Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: a blood test and urine sample collection..
- Who it may be relevant to
- Registry conditions: Liver Cirrhosis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.
Interventions
- Other a blood test and urine sample collection.
The study is offered to all patients who meet the inclusion criteria during their pre-transplant assessment by the principal investigator (during an existing visit). Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged.
Primary outcome measures
- hepatic transplantation reduces arterial calcification [Time frame: On the 7th day after surgery]
Secondary outcome measures (2)
- identify arterial calcification related factors [Time frame: On the 7th day after surgery]
- increase of PPi plasma level after liver transplantation [Time frame: at inclusion and at 3 months]
Eligibility criteria
Inclusion criteria
- everyone requiring liver transplantation for the treatment of a chronic liver disease
Exclusion criteria
- MELD score >25, viral replication
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
France · 1 center
- CHU de Nice — Nice
Identifiers
NCT: NCT07201649 · 24-PP-15